ATC Group: V10BX02 Samarium (153Sm) lexidronam

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V10BX02 in the ATC hierarchy

Level Code Title
1 V Various
2 V10 Therapeutic radiopharmaceuticals
3 V10B Pain palliation (bone seeking agents)
4 V10BX Various pain palliation radiopharmaceuticals
5 V10BX02 Samarium (153Sm) lexidronam

Active ingredients in V10BX02

Active Ingredient Description
Samarium ¹⁵³Sm lexidronam

Samarium has an affinity for skeletal tissue and concentrates in areas of bone turnover in intimate association with hydroxyapatite. It is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium (99mTc)-labelled biphosphonates on bone scan.

Related product monographs

Title Information Source Document Type  
QUADRAMET Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Estonia (EE)

France (FR)

Ireland (IE)

Lithuania (LT)

Poland (PL)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.